Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm Clinical Trial

Official title:

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03610490
• Other study ID #: 2017-0671
• Secondary ID: NCI-2018-0150920
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 17, 2018
• Est. completion date: January 31, 2025

Study information

• Verified date: January 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating lymphocytes MDA-TIL, made by collecting and growing specialized white blood cells (called T-cells) from a patient's tumor, may help to stimulate the immune system in different ways to stop tumor cells from growing.

Description:

PRIMARY OBJECTIVE:

I. To evaluate efficacy using objective response rate (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 in subjects with ovarian cancer, pancreatic ductal adenocarcinoma (PDAC), and colorectal cancers.

SECONDARY OBJECTIVES:

I. Determine the disease control rate (DCR) within and across cohorts. II. Determine the duration of response (DOR). III. Determine progression-free survival (PFS) and overall survival (OS). IV. Further characterize the safety profile of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) across multiple tumor types.

EXPLORATORY OBJECTIVES:

I. Establish duration of TIL persistence. II. Compare the molecular and immunological features of tumors before and after TIL therapy.

III. Prospectively evaluate the existing immunotherapy response criteria (immune-related Response Evaluation Criteria in Solid Tumors [irRECIST]) as the best response assessment tool for TIL therapy among a diverse group of solid tumors.

IV. Investigate TIL attributes (CD8 %, CD27 and CD28 expression) and correlation with response to therapy.

V. Assess tumor marker (CA19-9; CA-125) response in patients who produce this tumor marker.

VI. Assess Health-Related Quality of Life (HRQOL).

OUTLINE:

LYMPHODEPLETION REGIMEN: Patients receive cyclophosphamide intravenously (IV) over 2 hours on days -7 and -6, and fludarabine IV over 15-30 minutes on days -5 to -1 in the absence of disease progression or unacceptable toxicity.

T-CELL INFUSION: Patients receive autologous tumor infiltrating lymphocytes MDA-TIL IV over 45 minutes on day 0. Patients then receive IL-2 IV over 30 minutes on days 1-4 for up to 6 doses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at week 18, at 6, 9, 12, 18, and 24 months, and then every 3 months for up to 3 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: January 31, 2025
• Est. primary completion date: January 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subjects must be willing and able to provide informed consent

• Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1 at enrollment and within 7 days of initiating lymphodepleting chemotherapy

• Subjects must have an area of tumor amenable to excisional biopsy (core biopsies may be allowed) for the generation of TIL separate from, and in addition to, a target lesion to be used for response assessment

• Any prior therapy directed at the malignant tumor, including radiation therapy, chemotherapy, and biologic/targeted agents must be discontinued at least 28 days prior to tumor resection for preparing TIL therapy

• Absolute neutrophil count (ANC) >= 1000/mm^3 (within 7 days of enrollment)

• Hemoglobin >= 9.0 g/dL (transfusion allowed) (within 7 days of enrollment)

• Platelet count >= 100,000/mm^3 (within 7 days of enrollment)

• Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) and aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) < 2.5 x the upper limit of normal (ULN)

• Patients with liver metastases may have liver function test [LFT] =< 5.0 x ULN (within 7 days of enrollment)

• Calculated creatinine clearance (Cockcroft-Gault) >= 50.0 mL/min (within 7 days of enrollment)

• Total bilirubin =< 1.5 x ULN (within 7 days of enrollment)

• Prothrombin time (PT) & activated partial thromboplastin time (aPTT) =< 1.5 x ULN (correction with vitamin K allowed) unless subject is receiving anticoagulant therapy (which should be managed according to institutional norms prior to and after excisional biopsy) (within 7 days of enrollment)

• Negative serum pregnancy test (female subjects of childbearing potential) (within 7 days of enrollment)

• Subjects must not have a confirmed human immunodeficiency virus (HIV) infection

• Subjects must have a 12-lead electrocardiogram (EKG) showing no active ischemia and Fridericia's corrected QT interval (QTcF) less than 480 ms

• Subjects must also have a negative dobutamine stress echocardiogram before beginning treatment

• Subjects of childbearing potential must be willing to practice an approved highly effective method of birth control starting at the time of informed consent and for 1 year after the completion of the lymphodepletion regimen. Approved methods of birth control are as follows: hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation or hysterectomy; subject/partner status post vasectomy; implantable or injectable contraceptives; and condoms plus spermicide

• Able to adhere to the study visit schedule and other protocol requirements

• Pulmonary function tests (spirometry) demonstrating forced expiratory value (FEV) 1 greater than 65% predicted or forced vital capacity (FVC) greater than 65% of predicted

• Ovarian cancer cohort only: Subjects must have high grade non-mucinous histology (carcinosarcomas are allowed)

• Ovarian cancer cohort only: Subjects must have failed at least two prior lines of chemotherapy (i.e. frontline adjuvant chemotherapy plus one additional line for recurrent/progressive disease), or have platinum resistant disease

• Colorectal cohort only: Subjects with colorectal adenocarcinoma must have metastatic disease that is considered incurable with currently available therapies and have derived maximal benefit from or have become refractory to frontline conventional therapy (e.g. leucovorin calcium [calcium folinate], 5-fluorouracil and oxaliplatin [FOLFOX], leucovorin calcium, 5-fluorouracil, and irinotecan [FOLFIRI]).

• Colorectal cohort only: Subjects should have low disease burden such that in the treating physician's opinion the patient would not require additional intervening treatment for 7-8 weeks (required for TIL harvest and manufacturing)

• Pancreatic adenocarcinoma cohort only: Subjects must have histologically or cytologically documented diagnosis of PDAC with oligo-metastatic disease

• Pancreatic adenocarcinoma cohort only: Subjects must have progressed on, or received maximal benefit from, front-line therapy

• Pancreatic adenocarcinoma cohort only: Patients may have received unlimited lines of prior standard of care therapy

• Pancreatic adenocarcinoma cohort only: Patients with ascites or carcinomatosis are not eligible for the study

• Pancreatic adenocarcinoma cohort only: Patients will need an albumin of >= 3.0 mg/dL within 7 days of enrollment

• TREATMENT INCLUSION CRITERION: Within 24 h of starting lymphodepleting chemotherapy, subjects must meet the following laboratory criteria:

• Absolute neutrophil count (ANC) >= 1000/mm^3

• Hemoglobin >= 9.0 g/dL (transfusion allowed)

• Platelet count >= 100,000/mm3

• ALT/SGPT and AST/SGOT =< 2.5 x the upper limit of normal (ULN)

• Patients with liver metastases may have liver function tests (LFT) =< 5.0 x ULN

• Calculated creatinine clearance (Cockcroft-Gault) >= 50.0 mL/min

• Total bilirubin =< 1.5 X ULN

Exclusion Criteria:

• Active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system. Principal investigator (PI) or his/her designee shall make the final determination regarding appropriateness of enrollment

• Patients with active viral hepatitis

• Patients who have a left ventricular ejection fraction (LVEF) < 45% at screening

• Patients with a history of prior adoptive cell therapies

• Persistent prior therapy-related toxicities greater than grade 2 according to Common Toxicity Criteria for Adverse Events (CTCAE) v. 4.03, except for peripheral neuropathy, alopecia, or vitiligo prior to enrollment

• Primary immunodeficiency

• History of organ or hematopoietic stem cell transplant

• Chronic steroid therapy, however prednisone or its equivalent is allowed at < 10 mg/day

• Patients who are pregnant or nursing

• Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his/her designee, would prevent adequate informed consent

• History of clinically significant autoimmune disease including active, known, or suspected autoimmune disease. Subjects with resolved side effects from prior checkpoint inhibitor therapy, vitiligo, psoriasis, type 1 diabetes or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded

• History of clinically significant chronic obstructive pulmonary disease (COPD), asthma, or other chronic lung disease

• History of a second malignancy (diagnosed in the last 5 years). Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy

• History of known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to initiation of lymphodepletion

• Has received a live vaccine within 30 days prior to the initiation of lymphodepletion

• Patients who have a contraindication to or history of hypersensitivity reaction to any components or excipients of the TIL therapy or the other study drugs: NMA-LD (cyclophosphamide, mesna, and fludarabine); IL-2; any component of the TIL infusion product formulation including human serum albumin (HSA), IL-2, and dextran-40

• Any other condition that in the investigator's judgement would significantly increase the risks of participation

• Patient has any complication or delayed healing from excisional procedure that in the investigator's opinion would increase the risks of lymphodepletion, adoptive TIL therapy and adjuvant IL-2

• Patients has a decline in performance status to ECOG > 1 (at the visit prior to admission for lymphodepletion)

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma
• Carcinoma, Ovarian Epithelial
• Carcinosarcoma
• Colorectal Neoplasms
• Malignant Solid Neoplasm
• Metastatic Colorectal Adenocarcinoma
• Metastatic Ovarian Carcinoma
• Metastatic Pancreatic Ductal Adenocarcinoma
• Ovarian Neoplasms
• Platinum-Resistant Ovarian Carcinoma
• Recurrence
• Recurrent High Grade Ovarian Serous Adenocarcinoma
• Recurrent Ovarian Carcinosarcoma
• Refractory Colorectal Carcinoma
• Stage IV Colorectal Cancer AJCC v8
• Stage IVA Colorectal Cancer AJCC v8
• Stage IVB Colorectal Cancer AJCC v8
• Stage IVC Colorectal Cancer AJCC v8

Intervention

Biological:
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Given IV

Drug:
• Cyclophosphamide
Given IV
• Fludarabine
Given IV

Biological:
• Interleukin-2
Given IV

Other:
• Quality-of-Life Assessment
Ancillary studies

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (4)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	Bristol-Myers Squibb, Iovance Biotherapeutics, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Duration of tumor infiltrating lymphocyte (TIL) persistence	Duration of TIL persistence is determined by T cell receptor (TCR) sequencing of infused T cells serially isolated following MDA-TIL infusion, or alternatively iRepertoire assessment of messenger ribonucleic acid for the TCRs. A paired t-test will be used to examine the molecular and immunological features of tumors before and after TIL therapy. Pearson correlation coefficient and linear regression, when appropriate, will be used to quantify the relationship between phenotypic attributes (CD8 %, CD27 and CD28 expression, etc.) and response to therapy.	Up to 5 years
Other	Response	Will be determined by the immune-related response criteria. A paired t-test will be used to examine the molecular and immunological features of tumors before and after TIL therapy. Pearson correlation coefficient and linear regression, when appropriate, will be used to quantify the relationship between phenotypic attributes (CD8 %, CD27 and CD28 expression, etc.) and response to therapy.	Up to 5 years
Other	Assessment of immunological phenotype of autologous tumor infiltrating lymphocytes MDA-TIL	A paired t-test will be used to examine the molecular and immunological features of tumors before and after TIL therapy. Pearson correlation coefficient and linear regression, when appropriate, will be used to quantify the relationship between phenotypic attributes (CD8 %, CD27 and CD28 expression, etc.) and response to therapy.	At the time of infusion
Other	Tumor assessment	Will be determined by immunohistochemistry, TCR sequencing, and transcriptional analysis. A paired t-test will be used to examine the molecular and immunological features of tumors before and after TIL therapy. Pearson correlation coefficient and linear regression, when appropriate, will be used to quantify the relationship between phenotypic attributes (CD8 %, CD27 and CD28 expression, etc.) and response to therapy.	Up to 5 years
Other	Health-related quality of life	Will be assessed by European Organization for Research and Treatment of Cancer core 30 quality of life questionnaire. A paired t-test will be used to examine the molecular and immunological features of tumors before and after TIL therapy. Pearson correlation coefficient and linear regression, when appropriate, will be used to quantify the relationship between phenotypic attributes (CD8 %, CD27 and CD28 expression, etc.) and response to therapy.	Up to 5 years
Primary	Objective response rate (ORR)	Will be measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. ORR will use 80% confidence interval by the Wilson score method.	Up to 5 years
Secondary	Complete response rate (CRR)	Will be measured by RECIST 1.1 criteria. CRR will adopt the 2-sided 95% criteria.	Up to 5 years
Secondary	Disease control rate (DCR)	Will be measured by RECIST 1.1 criteria. DCR will adopt the 2-sided 95% criteria. DCR includes complete response, partial response, and stable disease.	Up to 5 years
Secondary	Duration of response (DOR)	Will be measured by RECIST 1.1 criteria. DOR will adopt the 2-sided 95% criteria.	Up to 5 years
Secondary	Progression-free survival (PFS)	Will be measured by RECIST 1.1 criteria. PFS will be summarized using Kaplan-Meier estimates.	At 6 and 12 months
Secondary	Overall survival (OS)	OS will be summarized using Kaplan-Meier estimates.	At 6 and 12 months
Secondary	Incidence of adverse events	Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Safety endpoints will include overall assessment of adverse events (AEs) including grade 3 or greater non-hematological toxicities, serious adverse events and treatment-emergent AEs by grade and relationship to the study treatment.	Up to 5 years

External Links

•   MD Anderson Cancer Center Website